15. 封入体筋炎 Inclusion body myositis Clinical trials / Disease details


臨床試験数 : 42 薬物数 : 60 - (DrugBank : 16) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 122

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04789070
(ClinicalTrials.gov)
January 1, 202215/2/2021Phase III Trial of Sirolimus in IBMA Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS)Inclusion Body MyositisDrug: Sirolimus;Drug: PlaceboUniversity of Kansas Medical CenterThe Perron InstituteNot yet recruiting45 YearsN/AAll140Phase 3United States
2NCT02481453
(ClinicalTrials.gov)
July 15, 201513/5/2015Rapamycine vs Placebo for the Treatment of Inclusion Body MyositisÉtude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMIInclusion Body Myositis (IBM)Drug: Rapamycin;Drug: PlaceboInstitut National de la Santé Et de la Recherche Médicale, FranceNULLCompleted45 Years85 YearsAll44Phase 2/Phase 3France